RIGL Q3 2019 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M+328.7% YoY

Gross Profit

$21M98.5% margin

Operating Income

-$12M-57.7% margin

Net Income

-$11M-55.1% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

+100.4%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$156M

Total Liabilities

$87M

Stockholders' Equity

$69M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$5M	+328.7%
Gross Profit	$21M	$5M	+328.4%
Operating Income	-$12M	-$24M	+50.6%
Net Income	-$11M	-$24M	+51.7%

Revenue Segments

Gross Product

$14M34%

Product

$12M28%

Contract Revenues From Collaborations

$9M22%

License

$8M19%

Research And Development Services And Others

$1M3%

Discounts And Allowances

-$3M-6%